Abstract

In recent years, medical image analysis has played a vital role in detecting diseases in their early stages. Medical images are rapidly becoming available for various applications to solve human problems. Therefore, complex medical features are needed to develop a diagnostic system for physicians to provide better treatment. Traditional methods of abnormality detection suffer from misidentification of abnormal regions in the given data. Visual-saliency detection methods are used to locate abnormalities to improve the accuracy of the proposed work. This study explores the role of a visual saliency map in the classification of Alzheimer’s disease (AD). Bottom-up saliency corresponds to image features, whereas top-down saliency uses domain knowledge in magnetic resonance imaging (MRI) brain images. The novelty of the proposed method lies in the use of an elliptical local binary pattern descriptor for low-level MRI characterization. Ellipse-like topologies help to obtain feature information from different orientations. Extensively directional features at different orientations cover the micro patterns. The brain regions of the Alzheimer’s disease stages were classified from the saliency maps. Multiple-kernel learning (MKL) and simple and efficient MKL (SEMKL) were used to classify Alzheimer’s disease from normal controls. The proposed method used the OASIS dataset and experimental results were compared with eight state-of-the-art methods. The proposed visual saliency-based abnormality detection produces reliable results in terms of accuracy, sensitivity, specificity, and f-measure.

Highlights

  • Alzheimer’s disease (AD) is the most common cause of progressive dementia in older adults [1]

  • The OASIS database consists of brain magnetic resonance imaging (MRI) images [35,36,37]

  • Crosssectional MRI and longitudinal MRI data are available in the OASIS dataset

Read more

Summary

Introduction

Alzheimer’s disease (AD) is the most common cause of progressive dementia in older adults [1]. It occurs due to the death of neurons in different parts of the brain, and throughout all of the areas of the brain at the final stage of AD. This disease generally occurs in older patients at an average age of 65 years and varies from individual to individual [2]. Disease severity can increase for ten years after the diagnosis. The causes and reasons for the disease are still unknown to the medical community. Current treatment methods help manage symptoms in patients with AD. No treatment is available to completely cure the disease even though several medicines have been approved and tested recently

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call